153 related articles for article (PubMed ID: 38656636)
1. Limited prognostic role of routine serum markers (AP, CEA, LDH and NSE) in oligorecurrent prostate cancer patients undergoing PSMA-radioguided surgery.
Mehring G; Steinbach C; Pose R; Knipper S; Koehler D; Werner S; Riethdorf S; von Amsberg G; Ambrosini F; Maurer T
World J Urol; 2024 Apr; 42(1):256. PubMed ID: 38656636
[TBL] [Abstract][Full Text] [Related]
2. Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.
Horn T; Krönke M; Rauscher I; Haller B; Robu S; Wester HJ; Schottelius M; van Leeuwen FWB; van der Poel HG; Heck M; Gschwend JE; Weber W; Eiber M; Maurer T
Eur Urol; 2019 Oct; 76(4):517-523. PubMed ID: 30987843
[TBL] [Abstract][Full Text] [Related]
3. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery.
Knipper S; Mehdi Irai M; Simon R; Koehler D; Rauscher I; Eiber M; van Leeuwen FWB; van Leeuwen P; de Barros H; van der Poel H; Budäus L; Steuber T; Graefen M; Tennstedt P; Heck MM; Horn T; Maurer T
Eur Urol; 2023 Jan; 83(1):62-69. PubMed ID: 35718637
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
5.
Maurer T; Robu S; Schottelius M; Schwamborn K; Rauscher I; van den Berg NS; van Leeuwen FWB; Haller B; Horn T; Heck MM; Gschwend JE; Schwaiger M; Wester HJ; Eiber M
Eur Urol; 2019 Apr; 75(4):659-666. PubMed ID: 29625755
[TBL] [Abstract][Full Text] [Related]
6. Prostate specific membrane antigen mRNA in blood as a potential predictor of biochemical recurrence after radical prostatectomy.
Joung JY; Cho KS; Chung HS; Cho IC; Kim JE; Seo HK; Chung J; Park WS; Choi MK; Lee KH
J Korean Med Sci; 2010 Sep; 25(9):1291-5. PubMed ID: 20808671
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficiency of repeat salvage lymph node dissection for recurrence of prostate cancer using PSMA-radioguided surgery (RGS) after prior salvage lymph node dissection with or without initial RGS support.
Falkenbach F; Knipper S; Koehler D; Ambrosini F; Steuber T; Graefen M; Budäus L; Eiber M; Lunger L; Lischewski F; Heck MM; Maurer T
World J Urol; 2023 Sep; 41(9):2343-2350. PubMed ID: 37515651
[TBL] [Abstract][Full Text] [Related]
8. Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study.
de Barros HA; van Oosterom MN; Donswijk ML; Hendrikx JJMA; Vis AN; Maurer T; van Leeuwen FWB; van der Poel HG; van Leeuwen PJ
Eur Urol; 2022 Jul; 82(1):97-105. PubMed ID: 35339318
[TBL] [Abstract][Full Text] [Related]
9. Value of
Rauscher I; Düwel C; Wirtz M; Schottelius M; Wester HJ; Schwamborn K; Haller B; Schwaiger M; Gschwend JE; Eiber M; Maurer T
BJU Int; 2017 Jul; 120(1):40-47. PubMed ID: 27862863
[TBL] [Abstract][Full Text] [Related]
10. [PSMA-radioguided surgery in localised recurrent prostate cancer].
Horn T; Rauscher I; Eiber M; Gschwend JE; Maurer T
Urologe A; 2017 Nov; 56(11):1417-1423. PubMed ID: 29022058
[TBL] [Abstract][Full Text] [Related]
11. Biochemical Response of <0.1 ng/ml Predicts Therapy-free Survival of Prostate Cancer Patients following Prostate-specific Membrane Antigen-targeted Salvage Surgery.
Knipper S; Lischewski F; Koehler D; Eiber M; van Leeuwen FWB; de Barros H; Berrens AC; Zuur L; van Leeuwen PJ; van der Poel H; Ambrosini F; Falkenbach F; Budäus L; Steuber T; Graefen M; Tennstedt P; Gschwend JE; Horn T; Heck MM; Maurer T
Eur Urol Oncol; 2024 May; ():. PubMed ID: 38729805
[TBL] [Abstract][Full Text] [Related]
12. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen.
Niho S; Nishiwaki Y; Goto K; Ohmatsu H; Matsumoto T; Hojo F; Ohe Y; Kakinuma R; Kodama T
Lung Cancer; 2000 Mar; 27(3):159-67. PubMed ID: 10699689
[TBL] [Abstract][Full Text] [Related]
13. PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy.
Wenzel M; Hussein R; Maurer T; Karakiewicz PI; Tilki D; Graefen M; Würnschimmel C
Urol Oncol; 2022 Jan; 40(1):7.e1-7.e8. PubMed ID: 34340868
[TBL] [Abstract][Full Text] [Related]
14. A Multicenter Prospective Clinical Trial of
McCarthy M; Francis R; Tang C; Watts J; Campbell A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
[TBL] [Abstract][Full Text] [Related]
16. EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer.
Falkenbach F; Ambrosini F; Tennstedt P; Eiber M; Heck MM; Preisser F; Graefen M; Budäus L; Koehler D; Knipper S; Maurer T
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894375
[TBL] [Abstract][Full Text] [Related]
17. 68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: A Prospective, 2-Center Study.
Zacho HD; Nielsen JB; Dettmann K; Haberkorn U; Langkilde NC; Jensen JB; Petersen LJ
Clin Nucl Med; 2018 Aug; 43(8):579-585. PubMed ID: 29916917
[TBL] [Abstract][Full Text] [Related]
18. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series.
Francolini G; Detti B; Bottero M; Zilli T; Lancia A; Bruni A; Borghesi S; Mariotti M; Castellucci P; Fanti S; Filippi AR; Teriaca MA; Maragna V; Aristei C; Mazzeo E; Livi L; Ingrosso G
Clin Transl Oncol; 2021 Feb; 23(2):364-371. PubMed ID: 32602076
[TBL] [Abstract][Full Text] [Related]
19. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres.
Jørgensen LG; Osterlind K; Genollá J; Gomm SA; Hernández JR; Johnson PW; Løber J; Splinter TA; Szturmowicz M
Br J Cancer; 1996 Aug; 74(3):463-7. PubMed ID: 8695366
[TBL] [Abstract][Full Text] [Related]
20. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.
Zhang L; Liu D; Li L; Pu D; Zhou P; Jing Y; Yu H; Wang Y; Zhu Y; He Y; Li Y; Zhao S; Qiu Z; Li W
BMC Cancer; 2017 Feb; 17(1):96. PubMed ID: 28152979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
